New Risk • May 05
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Earnings have declined by 20% per year over the past 5 years. New Risk • Apr 21
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₫2.63t (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.3% operating cash flow to total debt). Earnings have declined by 13% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (1.5% net profit margin). Market cap is less than US$100m (₫2.63t market cap, or US$99.9m). New Risk • Apr 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.3% operating cash flow to total debt). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.6% average weekly change). Profit margins are more than 30% lower than last year (1.5% net profit margin). New Risk • Apr 03
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 6.3% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.3% operating cash flow to total debt). Earnings have declined by 13% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (1.5% net profit margin). Board Change • Mar 29
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Ngoc Pham was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Mar 05
Cuu Long Pharmaceutical Joint Stock Company, Annual General Meeting, Apr 24, 2026 Cuu Long Pharmaceutical Joint Stock Company, Annual General Meeting, Apr 24, 2026. New Risk • Nov 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Profit margins are more than 30% lower than last year (2.5% net profit margin). Market cap is less than US$100m (₫2.46t market cap, or US$93.5m). Reported Earnings • Nov 01
Third quarter 2025 earnings released: ₫81.00 loss per share (vs ₫19.00 profit in 3Q 2024) Third quarter 2025 results: ₫81.00 loss per share (down from ₫19.00 profit in 3Q 2024). Revenue: ₫285.7b (up 21% from 3Q 2024). Net loss: ₫5.94b (down ₫7.35b from profit in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Sep 09
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₫24,800, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 17x in the Pharmaceuticals industry in Vietnam. Negligible returns to shareholders over past three years. Reported Earnings • Aug 01
Second quarter 2025 earnings released: ₫44.00 loss per share (vs ₫141 profit in 2Q 2024) Second quarter 2025 results: ₫44.00 loss per share (down from ₫141 profit in 2Q 2024). Revenue: ₫323.2b (up 14% from 2Q 2024). Net loss: ₫3.22b (down 132% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Jun 24
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₫24,800, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 18x in the Pharmaceuticals industry in Vietnam. Negligible returns to shareholders over past three years. Reported Earnings • May 05
First quarter 2025 earnings released: EPS: ₫342 (vs ₫303 in 1Q 2024) First quarter 2025 results: EPS: ₫342 (up from ₫303 in 1Q 2024). Revenue: ₫340.0b (up 22% from 1Q 2024). Net income: ₫25.0b (up 13% from 1Q 2024). Profit margin: 7.4% (down from 8.0% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. New Risk • Apr 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.3% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (₫1.73t market cap, or US$65.9m). Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₫23,300, the stock trades at a trailing P/E ratio of 31.8x. Average trailing P/E is 17x in the Pharmaceuticals industry in Vietnam. Total loss to shareholders of 19% over the past three years. Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₫19,850, the stock trades at a trailing P/E ratio of 27.1x. Average trailing P/E is 16x in the Pharmaceuticals industry in Vietnam. Total loss to shareholders of 42% over the past three years. Announcement • Mar 04
Cuu Long Pharmaceutical Joint Stock Company, Annual General Meeting, Apr 25, 2025 Cuu Long Pharmaceutical Joint Stock Company, Annual General Meeting, Apr 25, 2025. Announcement • Dec 02
Cuu Long Pharmaceutical Joint Stock Company Announces Executive Changes On November 29, 2024, Cuu Long Pharmaceutical Joint Stock Company announced the change in personnel as follows: The resignation of Mr. Nghiem Xuan Truong as Deputy Financial Director; The appointment of Mrs. Nguyen Lam Minh Thuong as Financial Director; The appointment of Mrs. Bui Thi My Dang as Chief Accountant. Effective from November 29, 2024. Reported Earnings • Nov 04
Third quarter 2024 earnings released: EPS: ₫19.00 (vs ₫8.00 in 3Q 2023) Third quarter 2024 results: EPS: ₫19.00 (up from ₫8.00 in 3Q 2023). Revenue: ₫235.6b (down 9.1% from 3Q 2023). Net income: ₫1.41b (up 146% from 3Q 2023). Profit margin: 0.6% (up from 0.2% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Board Change • Oct 25
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 7 new directors. 1 experienced director. 1 highly experienced director. 1 independent director (4 non-independent directors). Chairman of the Board Nguyen Van Sang is the most experienced director on the board, commencing their role in 2014. Independent Director Ngoc Pham was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Announcement • Sep 10
Cuu Long Pharmaceutical Joint Stock Company Announces Executive Changes Cuu Long Pharmaceutical Joint Stock Company announced the change in personnel as follows: Appointment: Mr. Nguyen Trong Duc; Newly appointed position: Deputy CEO in charge of production & SC; Effective date: September 06, 2024. Resignation: Mr. Nguyen Trong Duc; Resigned position: Deputy CEO in charge of sales and marketing; Effective date: September 06, 2024. Announcement • Jul 26
Cuu Long Pharmaceutical Joint Stock Company Announces Change of Branch Address Cuu Long Pharmaceutical Joint Stock Company announced the change of branch address as follows: New address: 36/12 Kinh Duong Vuong street, ward 13, district 6, HCM city. Old address: 312 Xuan Thuy street, Hoang Phat area, An Binh ward, Ninh Kieu district, Can Tho city. Reported Earnings • Apr 30
First quarter 2024 earnings released: EPS: ₫303 (vs ₫200 in 1Q 2023) First quarter 2024 results: EPS: ₫303 (up from ₫200 in 1Q 2023). Revenue: ₫277.9b (up 17% from 1Q 2023). Net income: ₫22.1b (up 52% from 1Q 2023). Profit margin: 8.0% (up from 6.2% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 6% per year. Valuation Update With 7 Day Price Move • Apr 12
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₫29,200, the stock trades at a trailing P/E ratio of 34.6x. Average trailing P/E is 15x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 3.9% over the past three years. Announcement • Apr 05
Cuu Long Pharmaceutical Joint Stock Company Announces Management Resignations Cuu Long Pharmaceutical Joint Stock Company received the resignation letter from Mrs. Tuong Thi Thu Hanh, Mrs. Nguyen Ngoc Bich as member of BODs and Mrs. Le Thi Thuong as member of the Supervisory Board. Announcement • Mar 01
Cuu Long Pharmaceutical Joint Stock Company, Annual General Meeting, Apr 25, 2024 Cuu Long Pharmaceutical Joint Stock Company, Annual General Meeting, Apr 25, 2024. Location: No.150, street 14, ward 5, Vinh Long city, Vinh Long province. Vinh Long Vietnam Reported Earnings • Jan 31
Full year 2023 earnings released: EPS: ₫845 (vs ₫1,591 in FY 2022) Full year 2023 results: EPS: ₫845 (down from ₫1,591 in FY 2022). Revenue: ₫1.14t (up 13% from FY 2022). Net income: ₫61.7b (down 45% from FY 2022). Profit margin: 5.4% (down from 11% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 4% per year. Reported Earnings • Jul 31
Second quarter 2023 earnings released: EPS: ₫242 (vs ₫357 in 2Q 2022) Second quarter 2023 results: EPS: ₫242 (down from ₫357 in 2Q 2022). Revenue: ₫258.8b (up 24% from 2Q 2022). Net income: ₫17.7b (down 31% from 2Q 2022). Profit margin: 6.8% (down from 12% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: ₫200 (vs ₫212 in 1Q 2022) First quarter 2023 results: EPS: ₫200. Revenue: ₫236.8b (up 8.9% from 1Q 2022). Net income: ₫14.6b (up 12% from 1Q 2022). Profit margin: 6.2% (up from 6.0% in 1Q 2022). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Feb 08
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₫28,100, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 13x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 29% over the past three years. Reported Earnings • Feb 01
Full year 2022 earnings released: EPS: ₫1,591 (vs ₫1,495 in FY 2021) Full year 2022 results: EPS: ₫1,591 (up from ₫1,495 in FY 2021). Revenue: ₫1.02t (up 44% from FY 2021). Net income: ₫111.6b (up 30% from FY 2021). Profit margin: 11% (down from 12% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Board Change • Nov 16
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Chairman of the Board Nguyen Van Sang is the most experienced director on the board, commencing their role in 2014. Independent Outside Director Hanh Thu Tuong was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Announcement • Jun 17
Cuu Long Pharmaceutical Joint Stock Company Provides Earnings Guidance for the Fiscal Year 2022 Cuu Long Pharmaceutical Joint Stock Company provided earnings guidance for the fiscal year 2022. For the period, the company expects net revenue to be VND 845,510 million. Announcement • May 28
Cuu Long Pharmaceutical Joint Stock Company, Annual General Meeting, Jun 14, 2022 Cuu Long Pharmaceutical Joint Stock Company, Annual General Meeting, Jun 14, 2022. Location: Times Tower – HACC 1 Complex Building, 35 Le Van Luong, Nhan Chinh, Thanh Xuan district Ha Noi Vietnam Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Truong Phi was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Mar 17
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Truong Phi was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Dec 18
Cuu Long Pharmaceutical Joint Stock Company Announces Suspension of Operation of Branches Cuu Long Pharmaceutical Joint Stock Company approved the suspension of operation of Long My branch and Vi Thanh branch in Hau Giang Province. Valuation Update With 7 Day Price Move • Dec 17
Investor sentiment improved over the past week After last week's 15% share price gain to ₫44,800, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 17x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 379% over the past three years. Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment improved over the past week After last week's 16% share price gain to ₫45,250, the stock trades at a trailing P/E ratio of 31.1x. Average trailing P/E is 17x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 392% over the past three years. Reported Earnings • Oct 29
Third quarter 2021 earnings released: EPS ₫291 (vs ₫273 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ₫149.5b (up 9.6% from 3Q 2020). Net income: ₫16.5b (up 6.4% from 3Q 2020). Profit margin: 11% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 54% per year whereas the company’s share price has increased by 50% per year. Reported Earnings • Aug 02
Second quarter 2021 earnings released: EPS ₫567 (vs ₫325 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₫188.7b (up 29% from 2Q 2020). Net income: ₫32.2b (up 74% from 2Q 2020). Profit margin: 17% (up from 13% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 17
Investor sentiment improved over the past week After last week's 19% share price gain to ₫52,500, the stock trades at a trailing P/E ratio of 42.1x. Average trailing P/E is 16x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 251% over the past three years. Valuation Update With 7 Day Price Move • May 22
Investor sentiment improved over the past week After last week's 21% share price gain to ₫36,100, the stock trades at a trailing P/E ratio of 29x. Average trailing P/E is 16x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 138% over the past three years. Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment deteriorated over the past week After last week's 21% share price decline to ₫25,800, the stock is trading at a trailing P/E ratio of 11.5x, down from the previous P/E ratio of 14.5x. This compares to an average P/E of 15x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders over the past three years are 20%. Valuation Update With 7 Day Price Move • Jan 16
Investor sentiment improved over the past week After last week's 19% share price gain to ₫30,300, the stock is trading at a trailing P/E ratio of 13.5x, up from the previous P/E ratio of 11.3x. This compares to an average P/E of 15x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders over the past three years are 35%. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment improved over the past week After last week's 16% share price gain to ₫28,800, the stock is trading at a trailing P/E ratio of 12.8x, up from the previous P/E ratio of 11.1x. This compares to an average P/E of 15x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders over the past three years are 30%. Is New 90 Day High Low • Jan 11
New 90-day high: ₫27,250 The company is up 42% from its price of ₫19,250 on 13 October 2020. The Vietnamese market is up 24% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Valuation Update With 7 Day Price Move • Dec 22
Investor sentiment improved over the past week After last week's 19% share price gain to ₫26,000, the stock is trading at a trailing P/E ratio of 11.6x, up from the previous P/E ratio of 9.7x. This compares to an average P/E of 14x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders over the past three years are 13%. Is New 90 Day High Low • Dec 15
New 90-day high: ₫21,400 The company is up 7.0% from its price of ₫19,950 on 15 September 2020. The Vietnamese market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Announcement • Dec 03
Cuu Long Pharmaceutical Joint Stock Company Announces Change of Personnel Cuu Long Pharmaceutical Joint Stock Company announced personnel change as: Deputy CEO, Luu Que Minh retires from December 01, 2020; Mr. Nguyen Trong Duc was appointed as Deputy CEO in charge of production as from December 01, 2020. Reported Earnings • Nov 01
Third quarter earnings released Over the last 12 months the company has reported total profits of ₫127.8b, with earnings increasing by ₫119.0b from the prior year. Total revenue was ₫687.2b over the last 12 months, down 11% from the prior year. Is New 90 Day High Low • Oct 20
New 90-day low: ₫19,000 The company is down 11% from its price of ₫21,350 on 22 July 2020. The Vietnamese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. 